Session F: Prevention of Hepatitis C
Tracks
Track 1
| Wednesday, September 11, 2019 |
| 4:15 PM - 5:45 PM |
| Montreal A & B, Level 11 |
Speaker
Dr Håvard Midgard
MD PhD
Oslo University Hospital
Hepatitis C reinfection among people who inject drugs: Should we worry?
4:15 PM - 4:35 PMBiography
Håvard Midgard is a specialist in internal medicine and gastroenterology/hepatology at Oslo University Hospital. He has a PhD on management of HCV infection among PWID. His main research interests include HCV reinfection, models of HCV care, HCV epidemiology and elimination strategies, liver fibrosis assessment and management of advanced liver disease/cirrhosis complications. He is a board member of INHSU and hosted the 2016 INHSU Symposium in Oslo.
Dr Andrew Scheibe
Technical Advisor
TB HIV Care
Opportunities and challenges for harm reduction and HCV prevention among people who use drugs: South African reflections
4:35 PM - 4:55 PMSpeaker Presentation
Biography
Dr Andrew Scheibe is a medical doctor who focuses on infectious diseases among people who use drugs. He has been working in the field of harm reduction and substance use for the past eight years. He is a senior technical advisor for TB HIV Care.
Dr. Naglaa Shoukry
Professor Of Medicine
Université de Montréal
What does the future hold for a hepatitis C vaccine?
4:55 PM - 5:15 PMBiography
Dr. Shoukry is a leader in studying immunity to HCV in people who inject drugs. She is the Director of the Canadian Network on Hepatitis C (CanHepC) that is working towards establishing a pipeline from research to implementation and to improve the lives of Canadians living with HCV.
Panel
Questions & Discussion
5:15 PM - 5:45 PMBiography
Chair
Niklas Luhmann
Technical Officer
Who
Natasha Martin
Associate Professor
University Of California San Diego
